Fundraising Fox
ACORN BIOVENTURES
Crossover fundNew York · Seed–Late Stage · 3 people tracked
Also known as ACORN CAPITAL ADVISORS, LLC
Find your way into ACORN BIOVENTURES
836 people in our graph share verified history with the ACORN BIOVENTURES team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Acorn Bioventures seeks paradigm-changing medical therapies backed by exceptional management teams, focusing on undiscovered or underappreciated assets in the biotech and medtech spaces. The firm leverages over 35 years of investment experience and structures flexible capital to support companies from seed stage through public markets, with a track record of supporting companies that have achieved IPOs, major acquisitions, and multi-billion-dollar valuations.
Source: firm website, verified Sep 22, 2026.
Team · 3 people
from public directories
What they invest in
from 17 of 17 portfolio companiesBiotech ×9AI & Machine Learning ×4Healthtech ×4Enterprise Software ×3SaaS ×3Creator Economy ×2Data & Infrastructure ×2Deep Tech ×2
HQs:United States×5Australia×4
Investments · 17 tracked
founders shown can be your intro pathBy year:2024 · 32023 · 12022 · 52021 · 42020 · 114 dated
Addex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.
BiotechHealthtechGeneva
Roger Mills(Executive Officer, Director)inMikhail Kalinichev(Executive Officer)inJean-Philippe Rocher(Executive Officer)inRobert Lutjens(Executive Officer)inTimothy Dyer(Executive Officer, Director)Vincent Lawton(Director)
Board seatIsaac Manke· per SEC Form D · $5.9M raise · filed Dec 2021
Co-investorsNew Enterprise Associates (NEA)Sofinnova PartnersSR One Capital Management
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies.
BiotechDigital HealthHealthtechMedical DevicesBoulder, US
Jason Leverone(Executive Officer)inSamuel Agresta(Executive Officer)inDylan Hartley(Executive Officer)inWendy Johnson(Executive Officer)Nicholas A. Saccomano(President and Chief Executive Officer and Director)
Board seatIsaac Manke· per SEC Form D
Co-investorsAccess BiotechnologyBoulder VenturesRiverVest Venture PartnersAbingworthNew Enterprise Associates (NEA)Novo Holdings
CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.
BiotechHealthtechMedical Devices
Arthur Kuan(Chairman and Chief Executive Officer)in
Co-investorsDecheng CapitalForesite CapitalLongitude CapitalPalm Drive CapitalRA CapitalTCG Crossover+2 more
Eliem Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies targeting immune-mediated diseases, with budoprutug, an anti-CD19 antibody designed to deplete B cells in conditions including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy and related B-cell mediated diseases.
BiotechWilmington, US
Valerie Morisset(Executive Officer)inErin Lavelle(Executive Officer)inRobert Azelby(Executive Officer, Director)James Bucher(Executive Officer)Leone Patterson(Director)
BoardAdam Rosenberg(Director)
Co-investorsManta Ray VenturesAccess BiotechnologyIntermediate Capital GroupLifeArc VenturesRA Capital
Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.
BiotechHealthtech
Shelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)inDavid Appugliese(Senior Vice President, Head of People)in
Co-investorsAtlas VentureOrbiMedAgent CapitalCU Healthcare Innovation FundOUP (Osage University Partners)Sanofi Ventures+2 more
Trovagene is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 inhibitor, for treatment of cancers including RAS-mutated metastatic colorectal cancer, pancreatic cancer, small cell lung cancer, triple-negative breast cancer, and chronic myelomonocytic leukemia, with the goal of combining it with standard chemotherapy agents to improve patient outcomes.
BiotechSan Diego, US
Thomas Adams(Executive Officer, Director)Antonius Schuh(Executive Officer, Director)inDavid Robbins(Executive Officer)inSteve Zanibobi(Executive Officer)
BoardGabriele Cerrone(Director)Gary Jacob(Director)
Complexica provides AI software for optimizing sales, marketing, and supply chain decisions for enterprise customers.
AI & Machine LearningEnterprise SoftwareLogistics & Supply ChainSaaSAdelaide, AU
Dr. Zbigniew Michalewicz(Chief Scientist)Matt Michalewicz(Chief Executive Officer)in
Co-investorsPerennial Partners
Additive provides a GenAI tool that extracts tax data from K-1, K-3, and related forms (including state forms, 199A, 926, and others), converting PDF tax packages into Excel workpapers or JSON via a web app, Excel add-in, or API.
AI & Machine LearningFintechSaaS
Venky Iyer(Founder)in
Co-investorsMantis CapitalAM VenturesBreakthrough VictoriaElad GilFred EhrsamImmad Akhund+2 more
Conflu-X Technology manufactures thermal management products including cold plates, intercoolers, and liquid cooling solutions for automotive, aviation, data center, defense, and industrial applications.
Advanced ManufacturingData & InfrastructureHardware
Co-investorsAM VenturesBreakthrough Victoria
Genero is a platform that connects marketers with independent creative talent and production partners on demand.
B2B MarketplacesCreator EconomyMarketing TechMelbourne, AU
Andrew Lane(Founder)in
Co-investorsBrick Capital VenturesEllerston Capital
Liquid Instruments develops Moku, a reconfigurable integrated test system for complex research and development applications.
Deep TechDeveloper ToolsEnterprise SoftwareHardware
Daniel Shaddock(CEO)inDanielle Wuchenich(Chief Operating Officer)in
Co-investorsAnzu PartnersBreakthrough VictoriaSignificant VenturesAcorn CapitalLockheed Martin VenturesMA Growth Ventures
Moku creates Moki, a collection of 8887 hand-assembled NFT characters built from 900+ traits, and develops games around them including an AI Fantasy Arena, a snack-combining puzzler, and an async autobattler.
AI & Machine LearningCrypto & Web3Gaming
Bruce Wasicsko(Founder)in
Co-investorsArca FundsBankless VenturesBig Brain HoldingsBlocktower CapitalContango Digital AssetsFormless Capital+4 more
mx51 provides a white-label merchant dashboard portal that gives payment providers' customers centralized access to real-time transaction reporting, analytics, and service management across multiple payment channels.
Data & InfrastructureEnterprise SoftwareFintechRetail TechSaaSSydney, AU
Victor Zheng(Chief Executive Officer and Co-Founder)inMagnus Hsu(Chief Operating Officer and Co-Founder)inVarghese Mathew(Chief Customer Officer)in
Co-investorsArtesianRampersandAcorn CapitalCultivation CapitalReinventure GroupSixThirty Ventures
Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease.
AI & Machine LearningBiotechDeep TechDigital HealthSouth San Francisco, US
Nancy Stagliano(CEO)in
Co-investorsKleiner PerkinsSoftBank GroupSoftBank Vision FundWestlake Village BioPartnersCowen Healthcare InvestmentsHBM Partners+1 more
Redbubble is an online marketplace where independent artists sell their designs printed on products such as apparel and other merchandise.
Creator EconomyE-commerceMarketplaces
Martin Hosking(Founder)in
Co-investorsBlackbird FoundryBlackbird VenturesPiton Capital LLP
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 7
6 IPOs · 1 acquisitionsAddex TherapeuticsNASDAQ: ADXNOnkure Therapeutics IncNASDAQ: OKURCG OncologyNASDAQ: CGONEliem TherapeuticsNASDAQ: CLYMQ32 BioNASDAQ: QTTBTrovageneNASDAQ: CRDFAdditiveacq. by Thomson Reuters
Frequently asked questions
- How many investments has ACORN BIOVENTURES made?
- ACORN BIOVENTURES has 17 tracked investments, 7 of which have exited, including 2 dated in the last 24 months.
- What stage does ACORN BIOVENTURES invest at?
- ACORN BIOVENTURES invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does ACORN BIOVENTURES focus on?
- ACORN BIOVENTURES focuses on Biotech, Medical Devices.
- Where is ACORN BIOVENTURES located?
- ACORN BIOVENTURES is headquartered in New York, US.
Co-investors · 8
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.
Flagship Pioneering is a firm that creates and builds companies to pioneer breakthroughs in science and technology for people and the planet, active for over 25 years.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
Aberdare Ventures is a venture capital firm based in Menlo Park, California. It invests exclusively in companies working to make healthcare more efficient, lower cost, and smarter.
Firms observed investing alongside ACORN BIOVENTURES, from public investor directories. Shared companies are the overlap with ACORN BIOVENTURES's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.